FDA weighs a new kind of flu shot based on technology RFK Jr. has questioned
The FDA is poised to render a decision on Moderna's mRNA-based flu shot, which could be the first of its kind to market. The decision is expected to reverberate throughout the biotech industry.
Related Markets
All MarketsMarket data may be delayed. Not financial advice.
💡 AI analysis provides alternative perspectives on current events